Abstract

Abstract Funding Acknowledgements Type of funding sources: None. Introduction-Purpose Both manidipine and delapril have been proven to have a neutral effect on lipids. Patients with idiopathic hypertension are being administered with the 30mg hydrochloric delapril and 10mg hydrochloric manidipine formulation. The purpose of this study was to investigate the effect of the fixed combination of delapril/manidipine 30/10mg on lipid and apolipoprotein levels as well as on TRG/ApoA-1 and TRG/HDL-C ratios as indicative markers of insulin resistance, in patients with stage 2 hypertension (systolic blood pressure (SBP) 160-179 mmHg and/or diastolic blood pressure (DBP) 100-109 mmHg) and with prediabetes (IFG/IGT), before and after the 3-month treatment. Methods 53 patients referred to our outpatient clinic for lipid metabolism disorders and met the study’s criteria were included, during the period 2014-2018. In the group of delapril/minidipine there were randomized 30 males and 23 females from whom 12 were smokers and 7 alcohol users). The patients’ BMI was 28.73 [27.73-30.3] and the values of SBP and DBP were: 156 [151-161] και 100 [88-101] mmHg, respectively. The serum lipid and apolipoprotein levels were measured before and after the 3-month treatment. Results The resulting variations of SBP and DBP levels, as well as the changes in lipid levels, apolipoprotein levels and TRG/ApoA-1 and TRG/HDL-C ratios are presented on Table 1. Conclusion From the sample group it can be observed that the 3-month combination therapy with manidipine/delapril improved statistically significantly both SBP and DBP levels (reduction by -13.58% and -13%, respectively). Concerning serum lipid levels, the combination therapy statistically significantly improved TCHOL, LDL-CHOL, and non-HDL-CHOL levels (decrease by 4.01%, 6.7% and 5.4%, p= 0.009, 0.006 and 0,08 respectively). The changes in apolipoprotein values were small and only ApoB values showed a statistically significant variation. Finally, there wasn’t a statistically significant improvement on neither TRG/ApoA-1 nor TRG/HDL-C ratios.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.